Young K. Chen,Toufike Kanouni,Stephen W. Kaldor,Jeffrey Alan Stafford,James Marvin Veal,Paula Alessandra Tavares-Greco,Matthew Michael Kreilein
申请号：
US16436541
公开号：
US20190367473A1
申请日:
2019.06.10
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.
